Although the downstream signaling of hinokiresinols remains to be addressed with detailed studies, our studies suggested that hinokiresinols are a promising candidate for stroke treatment without producing psychoactive side effects associated with CB1R activation. The gene discussed is CNR1; the disease is stroke disorder.